This research document defines 'disease stability' as a new therapeutic indicator for chronic obstructive pulmonary disease (COPD) and verifies its clinical significance. Stability is presented as an ...

Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive pulmonary disease (COPD), yet fatigue often persists despite rehabilitation. We ...

Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...

Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, ...

Macrolide therapy is an established and effective treatment for selected patients with chronic obstructive airways diseases who experience frequent exacerbations despite optimal therapy. Randomised ...

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk ...

New phase 3 data presented at ERS 2026 and published in the New England Journal of Medicine indicate that tozorakimab could reshape biologic treatment in COPD, delivering clinically meaningful ...

Laughter therapy reduced breathlessness in people with COPD, with benefits comparable to established pursed-lip breathing ...

On 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary ...

Researchers conducted a cohort study to compare lung cancer risk among patients with COPD and T2DM using SGLT2 inhibitors vs sulfonylureas.

Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...